Kineta Inc. And RLB Holdings Announce New Joint Venture To Address High-Need Therapeutics Including Autoimmune Diseases
4/15/2014 9:26:47 AM
SEATTLE--(BUSINESS WIRE)--Kineta, Inc., a biotechnology company focused on the development of immune-modulating drugs for critical diseases, and RLB Holdings, an investment fund founded by Ray and Lydia Bartoszek, have formed a joint venture, Kineta RLB, LLC, which will commercialize promising, high-value compounds in selective disease areas with unmet medical needs.
Help employers find you! Check out all the jobs and post your resume.
comments powered by